Methylene Blue

證據等級: L5

預測適應症: 3 個

Methylene Blue: From Methemoglobinemia to Bronchitis

One-Sentence Summary

Methylene blue (MB) is a phenothiazine compound with established clinical uses, most notably as first-line treatment for acquired methemoglobinemia and as an endoscopic diagnostic stain. The TxGNN model predicts it may be effective for Bronchitis, with 0 clinical trials and 10 publications currently supporting this direction — however, the literature connection is indirect and the overall recommendation is Hold.

Quick Overview

Item	Content
Original Indication	Acquired methemoglobinemia (recognized clinical use)
Predicted New Indication	Bronchitis
TxGNN Prediction Score	99.97%
Evidence Level	L5
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not currently available in this Evidence Pack. Based on known information, methylene blue is a phenothiazine dye with multiple pharmacological properties: it acts as a NADPH-dependent methemoglobin reductase cofactor to convert ferric (Fe³⁺) haemoglobin back to functional ferrous (Fe²⁺) form, and it also exhibits antimicrobial, antioxidant, and nitric oxide pathway-modulating activity.

The link between methylene blue and bronchitis in the TxGNN prediction appears to arise from indirect knowledge graph associations rather than direct therapeutic evidence. Methylene blue’s documented use in fibreoptic bronchoscopy — as a mucosal stain that selectively marks malignant bronchial tissue — creates graph edges connecting MB to the bronchial system. However, this is a diagnostic application, not a therapeutic one for bronchitis inflammation or infection.

No preclinical, animal model, or clinical data currently supports methylene blue as a treatment for acute or chronic bronchitis. The repurposing rationale for this indication is assessed as a likely false positive arising from indirect node connections in the knowledge graph. The high TxGNN score (0.9997) should be interpreted with caution given the complete absence of mechanistic and experimental support.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
9387672	1996	Diagnostic Study	Chinese Journal of Surgery	MB staining in fibreoptic bronchoscopy: 97.14% of malignant bronchial tumours stained positively vs. 8.33% of bronchitis cases — confirms diagnostic, not therapeutic, use
7313968	1981	Diagnostic Study	Terapevticheskii Arkhiv	Chromoendofibroscopy with MB for differential diagnosis of benign vs. malignant bronchial neoplasms — diagnostic technique study
8420409	1993	Methodological Study	Am Rev Respiratory Dis	MB evaluated as a tracer marker in bronchoalveolar lavage (BAL) quantitation alongside ⁹⁹ᵐTc-DTPA and other markers — technical/methodological application only
31419501	2020	Animal Study	J Ethnopharmacology	Lippia alnifolia essential oil induces tracheal relaxation via multiple pathways; bronchitis and asthma mentioned as traditional indication context — MB not involved
21767626	2011	Animal Study	J Ethnopharmacology	Aloysia gratissima antidepressant effects via L-arginine/NO/cGMP pathway; bronchitis mentioned only as a traditional use — MB not involved
29254574	2018	Analytical Chemistry	Analytica Chimica Acta	Electrochemical aptasensor for theophylline detection; bronchitis cited as disease context for theophylline use — MB not involved
2749902	1989	Basic Research	Tsitologiia	MB (as “chromosmon”) studied for methemoglobin reduction in erythrocytes — pharmacological mechanism study, no bronchitis relevance
6121761	1982	Pharmacology Study	Int J Clin Pharmacol Ther Toxicol	MB used as an indicator-dilution marker to measure circulation time in cardiovascular studies — no bronchitis relevance
20084922	2009	Case Report	Mikrobiyoloji Bulteni	Case of Moraxella catarrhalis endocarditis; bronchitis mentioned as one of M. catarrhalis’ common manifestations — MB not involved
17120034	2007	Case Report	Eur J Pediatrics	Isolated tracheoesophageal fistula diagnosed in a child; MB used in diagnostic contrast studies — bronchitis was a differential diagnosis

Safety Considerations

Drug Interactions: A total of 186 drug interactions have been identified. Representative interactions by severity:

Severity	Interacting Drugs
Major	Ondansetron, Granisetron, Dolasetron, Palonosetron (5-HT₃ antagonists); Lorcaserin, Fenfluramine, Dexfenfluramine (serotonergic agents); Morphine, Opium (opioids); Ephedrine, Phentermine, Mazindol, Diethylpropion, Isometheptene (sympathomimetics); Bupropion (noradrenaline–dopamine reuptake inhibitor)
Moderate	Epinephrine, Epinephrine (ophthalmic), Epinephrine (topical), Ephedrine (nasal)

Pattern note: The clustering of Major interactions with serotonergic drugs (5-HT₃ antagonists, serotonin-releasing agents) is consistent with methylene blue’s known MAO-inhibitory activity, which can precipitate serotonin syndrome — a potentially life-threatening interaction. Co-administration with serotonergic medications should be avoided or managed with extreme caution.

Conclusion and Next Steps

Decision: Hold

Rationale: The bronchitis prediction carries an L5 evidence level with zero registered clinical trials and no literature directly supporting methylene blue as a bronchitis therapy. The retrieved publications relate exclusively to MB’s diagnostic use in bronchoscopy or mention bronchitis only as background context in unrelated studies. The repurposing rationale identifies this prediction as a knowledge graph false positive.

To proceed, the following is needed:

Preclinical in vitro or in vivo data demonstrating a direct therapeutic effect of MB on bronchial inflammation or infection
A plausible mechanistic hypothesis linking MB’s antimicrobial or nitric oxide-modulating properties to bronchitis pathophysiology
Mechanism of action (MOA) data from DrugBank (currently unavailable — Data Gap DG002) to enable proper mechanistic analysis
TFDA package insert safety data (currently unavailable — Data Gap DG001) before any clinical feasibility assessment

Note on other TxGNN predictions: Two additional indications were evaluated in this Evidence Pack. Methemoglobinemia due to methemoglobin reductase deficiency (rank 3) is rated L3 / Proceed with Guardrails, with a sound mechanistic basis — MB bypasses the deficient NADH pathway via an independent NADPH-dependent route, supported by human and veterinary case reports. This indication may be a more actionable repurposing candidate and merits a dedicated evaluation report.

This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.